The life sciences sector is made up of a diverse ecosystem of companies and segments. They range from massive global pharma companies and regional lab powerhouses to small startup device manufacturers and innovative biotech research labs. No two life sciences companies face the same challenges or opportunities. And there is no ‘typical’ life sciences CEO.
The 2024 KPMG Life Sciences CEO Outlook, a survey of 120 life sciences CEOs from around the world suggests there are common themes and strategies at play. As life sciences organisations across the spectrum focus on driving innovation, many are struggling to accelerate digitalisation and the adoption of AI. They recognise the importance of environmental, social and governance (ESG) on public trust and growth but aren’t sure they can meet their net zero objectives. Talent gaps and capability shortages emerge as continuous themes throughout.
